AbbVie buys time between doses. CAR-T reaches solid tumours. The real work begins after the announcement.
- AbbVie just spent $10.9 billion on a lighter treatment calendar.
Its Apogee acquisition is a bet that, in chronic immunology, fewer injections may become a serious competitive advantage. - CAR-T has finally crossed into solid tumours.
China has approved CARsgen’s satri-cel for advanced gastric cancer. The scientific barrier moved. The delivery barrier did not disappear. - The GLP-1 access gap has reached a courtroom.
Novo Nordisk secured an interim order against compounded semaglutide products in South Africa. Safety, affordability and regulation are now colliding in public. - A hospital-only class of antibiotics has found an oral route.
The FDA approved Utebzi, the first oral carbapenem for certain complicated urinary tract infections. - How sick is sick enough? New Medicaid work requirements turn illness into an administrative test, forcing people to prove they meet an exemption or the 80-hour rule before coverage is put at risk.
- Meanwhile, the industry is still looking for a way into the hardest tumours.
Jazz and AbCellera are putting money behind next-generation T-cell engagers for gastrointestinal cancers and other solid tumours. - And Brussels is trying to fix the regulatory gate.
Europe’s proposed MDR/IVDR revision could shape how quickly the diagnostics and devices behind personalised medicine can reach the market.
| This is not another health news digest. It’s a twice-weekly readout of where evidence meets power and where power must turn into action. |
AbbVie just bought a lighter calendar
AbbVie’s $10.9 billion purchase of Apogee Therapeutics is a large deal with a surprisingly practical premise: patients with chronic inflammatory disease may value fewer interruptions to their lives.
Apogee’s lead asset, zumilokibart, is an investigational IL-13 treatment being developed for conditions including atopic dermatitis and asthma. It is being studied as a subcutaneous injection given every three or six months. By comparison, Dupixent, marketed by Sanofi and Regeneron, is typically administered every two weeks for atopic dermatitis. AbbVie announcement | Reuters reporting
That is why this is more than another immunology acquisition.
In chronic disease, dose frequency affects adherence, clinic capacity, patient time, caregiver burden and payer calculations. A treatment that works well but repeatedly disrupts life carries a hidden cost. One that works with fewer visits and fewer injections may shift the whole value conversation.
AbbVie is clearly strengthening its next-generation immunology pipeline as Humira’s loss of exclusivity reshapes the company and as future pressure builds around Skyrizi and Rinvoq.
The prize is not merely a molecule.
It is time between doses.
CAR-T broke into solid tumours. Access still has a lock on the door.
China’s regulator has approved CARsgen Therapeutics’ satricabtagene autoleucel, known as satri-cel, for advanced gastric cancer. CARsgen describes it as the world’s first approved CAR-T therapy for a solid tumour.
CAR-T has already changed outcomes in parts of haematology. Solid tumours have been a much tougher frontier. Engineered immune cells must identify the right target, navigate a hostile tumour microenvironment, persist long enough to work and avoid toxicity that health systems cannot safely manage. CARsgen announcement | Reuters reporting
Satri-cel targets Claudin18.2 and is approved in China for eligible patients with advanced gastric or gastroesophageal-junction adenocarcinoma after previous treatment failure. Now the harder questions arrive.
Who will be tested for the target? Which hospitals can deliver a personalised cell therapy safely? Who will manage cytokine release syndrome and other toxicities? What happens to patients outside top-tier cancer centres? And, eventually, who pays?
Public fights, private stakes
The shortcut is in court.
South Africa’s High Court has granted Novo Nordisk an interim order stopping local pharmacy group iDexis from compounding, supplying and marketing semaglutide-based weight-loss products while regulatory processes and potential review proceedings continue. Reuters reporting
Novo Nordisk argued that iDexis was selling unregistered semaglutide medicines without complying with South Africa’s Medicines Act. The order is interim, but the access problem behind it is not. Demand for GLP-1 medicines is surging. So are the pressure points: price, supply, quality, prescribing, public expectations and the temptation for unauthorised alternatives to fill a market gap.
This is not a simple story of one company against one pharmacy group.
There is a legitimate safety question. Patients deserve medicines that meet proper quality and regulatory standards. But there is also a harder policy question: what happens when the authorised route does not meet the demand created by medical need, consumer demand and affordability pressure?
Court orders can remove an option.
They do not automatically create access.
Access
A hospital antibiotic gets a ticket home
This is not the week’s flashiest pharmaceutical story.
It may be one of the most useful.
The US Food and Drug Administration has approved Utebzi, or tebipenem pivoxil, the first oral carbapenem antibiotic for complicated urinary tract infections, including pyelonephritis, in adults with limited or no alternative oral treatment options.
That matters because carbapenems have historically been administered intravenously. In the pivotal trial, oral Utebzi was compared with intravenous imipenem-cilastatin in hospitalised adults with complicated urinary tract infections.
The indication is specific, and it should stay that way. This is not a universal answer to antimicrobial resistance. Nor does an oral route remove the need for careful antimicrobial stewardship. FDA approval notice | GSK announcement
But for the right patient, it could change where treatment happens.
Less dependence on IV treatment can mean fewer hospital visits, less disruption for families and more flexibility for clinicians trying to manage serious infections outside the traditional hospital pathway. GSK says Utebzi is expected to become available to US patients by the end of 2026.
Human reality check
How sick is sick enough?
That is the wrong question.
From January 2027, certain adults on Medicaid expansion coverage will have to show 80 hours a month of work, education, community service or other qualifying activity, unless they qualify for an exemption. If compliance or exemption status cannot be verified, coverage can be put at risk. CMS
The politics are familiar. Public benefits should support work.
But chronic illness does not fit paperwork. Cancer fatigue, depression, diabetes, Long COVID, autoimmune disease and treatment side effects do not always appear neatly in an eligibility system. Medicaid is not a bonus. It is the route to medicines, scans, primary care, cancer treatment and mental-health support for millions of people.
The law includes medical exemptions. The problem is turning clinical complexity into forms, software and verification systems without pushing ill people out of care. Previous work-requirement programmes showed how easily coverage can be lost through reporting failures, even by people who should remain eligible. KFF
This is personalised medicine in reverse.
A health system should not ask whether someone is sick enough on paper. It should protect care when life is unstable.
Industry signal
Jazz is putting T cells on the trail.
Some oncology deals arrive with a late-stage asset and a valuation headline. This one arrives with a question: can the immune system be directed into solid tumours with enough precision to matter?
Jazz Pharmaceuticals and AbCellera have announced a preclinical research, option and licence agreement to develop next-generation T-cell-engaging multispecific antibodies for gastrointestinal cancers and other solid tumours. Jazz Pharmaceuticals and AbCellera announcement
AbCellera will receive $56 million in upfront payments for the first two programmes. If Jazz exercises its options to develop resulting candidates, AbCellera could receive up to $792 million per programme in option fees and development, regulatory and commercial milestones, as well as royalties.
In the same week that CAR-T therapy has reached its first solid-tumour approval, another company is placing a different bet on how to make immune therapies work in cancers where the biology has repeatedly resisted them.
T-cell engagers are designed to bring T cells into contact with cancer cells. The ambition is clear. The difficulty is obvious.
The immune system has to find the right target, arrive in the right place, stay active in a hostile environment and know what not to attack. That is the maze. Jazz and AbCellera are betting it can be mapped.
Policy watch
Europe is fixing the gate after the queue formed.
Brussels has a habit of making major health-system decisions sound like technical housekeeping.
This is not technical housekeeping.
The European Commission has proposed a targeted revision of the EU’s medical-device and in-vitro-diagnostic rules, known as the MDR and IVDR. The stated aim is to make the framework simpler, faster and more effective while supporting innovation, digitalisation, competitiveness and patient safety. European Commission proposal and legislative update
For the diagnostics community, this is not an abstract legislative exercise.
An in-vitro diagnostic can be the gatekeeper to an entire care pathway. No test means no biomarker result. No biomarker result can mean no eligibility signal. No eligibility signal can mean no referral, treatment match or trial opportunity.
The Commission’s proposal is not law yet. The European Parliament and Council still need to adopt it.
But the direction matters.
Europe cannot claim to want world-leading personalised medicine while leaving the tests, devices and digital tools behind it trapped in a regulatory bottleneck.
The June watchlist
June is not done. The second half of the month brings decisions and meetings that could shape the next access fights.
| 22-25 June, Amsterdam: |
| EMA committee for medicinal products for human use plenary. |
| 22-25 June, San Diego, US: |
| BIO International Convention gathers the biotech ecosystem. (BIO.) |
| 24-27 June, Philadelphia, US: |
| AACR’s malignant lymphoma meeting puts blood cancers back in the precision medicine spotlight. (AACR.) |
Follow the last-mile conversation!
IPM Alliance tracks the decisions, bottlenecks and implementation gaps shaping personalised medicine access. Follow us for briefings, events, policy signals and practical insights from across regions and disease areas.
We want to hear from you
When a patient becomes eligible for personalised care, where does the system most often lose them: identification, testing, referral, reimbursement, delivery capacity or equity?
Know someone who should be reading this?
IPM Brief is built for people working where science, policy and patient access collide. If one colleague would find this useful, forward it to them and help bring them into the conversation.
International Alliance for Personalised Medicine
Avenue de l’Armée / Legerlaan 10, 1041 Brussels, Belgium
This email was sent to jayasinghtec29@gmail.com. You are receiving this email because you are part of the IPM Alliance network or have engaged with our activities, briefings, events, or policy work.
